WALTHAM, Mass.--(BUSINESS WIRE)--Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that Robert J. Palmisano is joining its Board of Directors. Mr. Palmisano is the current President & CEO of Wright Medical Group, Inc. (NASDAQ: WMGI).
Mr. Palmisano has significant experience leading publicly-traded medical device companies, most recently serving as President & CEO of ev3, Inc., a global endovascular device company, from April 2008 to July 2010 when it was acquired by Covidien plc. Prior to ev3, Mr. Palmisano was an instrumental leader in the ophthalmic medical device industry serving as President & CEO of IntraLase Corp. from 2003 to 2007, when it was acquired by AMO and serving as President & CEO of Summit Technology, Inc. from 1997 to 2000 when it was acquired by Alcon, Inc. Earlier in his career, he served in various executive positions at Bausch & Lomb Incorporated. During the past five years, Mr. Palmisano served on the Board of Directors of ev3, Inc., Osteotech, Inc., Abbott Medical Options, Inc., and Bausch & Lomb. Mr. Palmisano holds a B.A. degree in Political Science from Providence College and currently serves on its Board of Trustees.
“I have been excited about the potential of cross-linking technology since my days with IntraLase. I am thrilled to join David Muller and the Avedro team to do whatever I can to help bring this technology to the market,” Palmisano stated.
David Muller, PhD, CEO of Avedro states, “After my departure from Summit Technology, Bob did an outstanding job in providing strategic guidance to the company, thus positioning it for growth and ultimately to be acquired. I am now looking forward to working with him on building the future of Avedro and look forward to a very successful outcome.”
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking and refractive correction. Avedro’s products include capital equipment and related single dose pharmaceuticals.
Avedro distributes its products in 62 countries through 33 ophthalmic distributors with 115 sales and service representatives. Avedro products that have received CE Mark include: the KXL® System for performing Lasik Xtra® and Accelerated Cross-Linking, the KXL II™ System for performing PiXL™, and the Avedro family of proprietary single dose pharmaceutical formulations.
Avedro’s KXL System and single dose pharmaceutical products are currently being used in three Phase III US clinical trials involving over 100 US clinical sites. Avedro products are not for sale in the US.